
Releases
Capricor Therapeutics Faces Class Action Suit Following FDA Data Critique
Investors who acquired Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, have until September 28 to seek lead plaintiff status in a class action lawsuit filed in the Southern District of California, alleging the company misled shareholders regarding the regulatory approval process for its lead drug candidate, Deramiocel.

























